NEW YORK (Reuters) -Repligen, a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings, a vaccine capping reagent vendor that has a market value of about $2.5 billion, ...
Repligen Corp (NASDAQ:RGEN) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of ...
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 4.4% in the afternoon session after investment firm Stifel reiterated its Buy rating and maintained a $207.00 price ...
Repligen's price target has recently seen a modest increase, with fair value estimates rising from $179.78 to $184.76. This reflects cautious optimism from analysts. The upward revision is rooted in ...
A month has gone by since the last earnings report for Repligen (RGEN). Shares have lost about 12.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up ...
Hosted on MSN
Repligen’s (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results , with sales up 14.8% year on year to $182.4 million. The company’s full-year revenue guidance of $725 ...
Repligen RGEN shares soared 3.7% in the last trading session to close at $116.11. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...
For the three-month stretch ending in March, Repligen Corporation turned record-breaking revenue of $206.4 million into operating earnings of $0.92 per share. Organic revenue was up 44% year over year ...
NEW YORK, Aug 16 (Reuters) - Repligen (RGEN.O), opens new tab, a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings (MRVI.O), opens new tab, a vaccine capping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback